ArticleFrontiers in pharmacology2025
Explore the changes of metabolites in feces and serum of acute pancreatitis patients with different etiologies by LC-MS based metabolomics strategy.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pancreatitis (AP) is a common abdominal inflammatory disease, which is mainly caused by gallstones, hyperlipidemia, and so on. Previous studies have explored the changes of serum metabolites in patients with AP. However, whether different etiologies have distinct impacts on the fecal and serum metabolites of the AP patients is still in suspense. Aim: This investigation was designed with dual objectives: (1) to systematically delineate etiology-specific alterations in metabolic profiles and associated pathway perturbations in AP cohorts, and (2) to evaluate their potential as diagnostic biomarkers and pathogenesis-targeted therapeutic strategies. Methods: Fifteen stool samples and fifteen serum samples from the patients with biliary acute pancreatitis (BAP) and hyperlipidemic acute pancreatitis (HAP), respectively, were analyzed. Metabolites were quantified by using ultrahigh performance liquid chromatography-mass spectrometry (UPLC-MS). The anti-inflammatory properties of Gibberellin A4 (GA4) and catechin were verified by RT-qPCR Results: The metabolites in feces and serum of the AP group were significantly different from that of the control group. Compared with the control group, a total of 10 fecal metabolites were significantly altered in the AP group. In the serum metabolites, five differential metabolites were identified between the AP and control groups. Receiver operating characteristic analysis of the subjects found that important differential metabolites can distinguish AP patients with different etiology from healthy people, and Conclusion: The significant differential metabolites between AP patients and healthy people can clearly distinguish the two groups, and GA4 and catechin have anti-inflammatory effects on pancreatic cell lines. The identification of distinct metabolites enabled to distinguish the AP patients with different etiologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.